Patient genetics and anti-IL17 therapy response have not been found to be correlated.

Published Date: 13 Sep 2023

Secukinumab, an anti-IL17 drug frequently used to treat inflammatory conditions like psoriasis and arthritis, was the subject of a recent study that examined the impact of patient genetics on their response to the drug. No connection between a patient's was discovered.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot